718 related articles for article (PubMed ID: 29455320)
21. Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
Pernot J; Puzenat E; Magy-Bertrand N; Manzoni P; Gondouin A; Bourdin H; Simon-Rigaud ML; Regnard J; Degano B
Respiration; 2012; 84(6):461-8. PubMed ID: 22301769
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis.
Yanaba K; Hasegawa M; Hamaguchi Y; Fujimoto M; Takehara K; Sato S
Clin Exp Rheumatol; 2003; 21(4):429-36. PubMed ID: 12942693
[TBL] [Abstract][Full Text] [Related]
23. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis.
Hasegawa M; Fujimoto M; Hamaguchi Y; Matsushita T; Inoue K; Sato S; Takehara K
J Rheumatol; 2011 May; 38(5):877-84. PubMed ID: 21239758
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
[TBL] [Abstract][Full Text] [Related]
25. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
[TBL] [Abstract][Full Text] [Related]
26. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
[TBL] [Abstract][Full Text] [Related]
27. Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease.
Fu H; Zheng Z; Zhang Z; Yang Y; Cui J; Wang Z; Xue J; Chi S; Cao M; Chen J
Clin Rheumatol; 2023 Jul; 42(7):1917-1929. PubMed ID: 36929316
[TBL] [Abstract][Full Text] [Related]
28. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
Ishikawa N; Hattori N; Yokoyama A; Kohno N
Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
[TBL] [Abstract][Full Text] [Related]
29. Disease progression and changes in KL-6 in patients with limited cutaneous systemic sclerosis-associated interstitial lung disease.
Takei R; Yamano Y; Kataoka K; Fukihara J; Sasano H; Yokoyama T; Matsuda T; Kimura T; Kondoh Y
Respir Investig; 2024 Jan; 62(1):44-48. PubMed ID: 37944381
[TBL] [Abstract][Full Text] [Related]
30. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
[TBL] [Abstract][Full Text] [Related]
31. Serum YKL-40 and Serum Krebs von den Lungen-6 as Potential Predictive Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Liang B; Zhang Y; Ke D; Yan R; Jiang MN; Li L; Zhang LX; Zhao XG; Yuan GP; Xu B; Liu XM
Immunol Invest; 2024 Jun; ():1-12. PubMed ID: 38900045
[TBL] [Abstract][Full Text] [Related]
32. Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease.
Györfi AH; Filla T; Dickel N; Möller F; Li YN; Bergmann C; Matei AE; Harrer T; Kunz M; Schett G; Distler JHW
Rheumatology (Oxford); 2024 Apr; 63(4):962-969. PubMed ID: 37421394
[TBL] [Abstract][Full Text] [Related]
33. Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer.
Park HK; Yoon CS; Na YO; Lee JK; Oh HJ; Park HY; Kho BG; Kim TO; Shin HJ; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Park CK
Sci Rep; 2023 Oct; 13(1):18126. PubMed ID: 37872370
[TBL] [Abstract][Full Text] [Related]
34. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
[TBL] [Abstract][Full Text] [Related]
35. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease.
De Santis M; Bosello SL; Peluso G; Pinnelli M; Alivernini S; Zizzo G; Bocci M; Capacci A; La Torre G; Mannocci A; Pagliari G; Varone F; Pistelli R; Danza FM; Ferraccioli G
Clin Respir J; 2012 Jan; 6(1):9-17. PubMed ID: 21801327
[TBL] [Abstract][Full Text] [Related]
36. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
[TBL] [Abstract][Full Text] [Related]
37. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence.
Christmann RB; Wells AU; Capelozzi VL; Silver RM
Semin Arthritis Rheum; 2010 Dec; 40(3):241-9. PubMed ID: 20494406
[TBL] [Abstract][Full Text] [Related]
38. Forensic application of three interstitial pneumonia markers: search for new pneumonia markers in dead bodies.
Okaba K; Inokuchi G; Horioka K; Iwase H; Inoue H; Motomura A; Ishii N; Moue C; Shiomi T; Yajima D
Int J Legal Med; 2024 Jul; 138(4):1583-1592. PubMed ID: 38379061
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
[TBL] [Abstract][Full Text] [Related]
40. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.
Hasegawa M; Asano Y; Endo H; Fujimoto M; Goto D; Ihn H; Inoue K; Ishikawa O; Kawaguchi Y; Kuwana M; Muro Y; Ogawa F; Sasaki T; Takahashi H; Tanaka S; Takehara K; Sato S
Rheumatology (Oxford); 2012 Jan; 51(1):129-33. PubMed ID: 22072085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
